InsiderSignal.AI

InsiderSignal.ai

BLCO - Bausch & Lomb Corp

Insider Purchase by Saunders Brent L (CEO, COB)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Saunders Brent L, serving as CEO, COB at Bausch & Lomb Corp (BLCO), purchased 14,700 shares at $17.14 per share, for a total transaction value of $251,958.00. Following this transaction, Saunders Brent L now holds 981,275 shares of BLCO.

This purchase represents a 2.00% increase in Saunders Brent L's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, March 6, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, March 10, 2026, 4 days after the trade was made.

Bausch & Lomb Corp operates in the HEALTHCARE sector, specifically within the MEDICAL INSTRUMENTS & SUPPLIES industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Saunders Brent L

Saunders Brent L

CEO, COB

Brent L. Saunders (born 1970) is an American biopharmaceutical executive serving as Chairman and CEO of Bausch & Lomb Corporation (BLCO) since March 2023, his second tenure in the role after leading the company from 2010 to 2013, during which he oversaw its $8.7 billion acquisition by Valeant Pharmaceuticals (now Bausch Health).[[1]](https://brentsaunders.com)[[2]](https://en.wikipedia.org/wiki/Brent_Saunders)[[3]](https://brightinsight.com/profiles/brent-saunders)[[4]](https://www.fiercepharma.com/pharma/10-years-after-selling-bausch-lomb-controversial-dealmaker-saunders-back-ceo) Saunders began his career as Chief Compliance Officer at Thomas Jefferson University Health System, advanced to Partner and Head of Compliance at PricewaterhouseCoopers, and held key roles at Schering-Plough, including President of Global Consumer Health Care and leading its merger with Merck.[[2]](https://en.wikipedia.org/wiki/Brent_Saunders)[[3]](https://brightinsight.com/profiles/brent-saunders)[[5]](https://childmind.org/bio/brent-saunders/) He later served as CEO of Forest Laboratories (acquired by Actavis), CEO of Actavis (which merged with Allergan in a $70.5 billion deal), and Chairman, President, and CEO of Allergan until its $63 billion sale to AbbVie in 2020.[[1]](https://brentsaunders.com)[[2]](https://en.wikipedia.org/wiki/Brent_Saunders)[[4]](https://www.fiercepharma.com/pharma/10-years-after-selling-bausch-lomb-controversial-dealmaker-saunders-back-ceo)[[5]](https://childmind.org/bio/brent-saunders/) With over 20 years of experience, Saunders has orchestrated M&A deals exceeding $300 billion and currently chairs The Beauty Health Company and other innovation firms, while serving on boards like Cisco and contributing to healthcare accessibility.[[1]](https://brentsaunders.com)[[3]](https://brightinsight.com/profiles/brent-saunders)[[5]](https://childmind.org/bio/brent-saunders/)

View full insider profile →

Trade Price

$17.14

Quantity

14,700

Total Value

$251,958.00

Shares Owned

981,275

Trade Date

Friday, March 6, 2026

10 days ago

SEC Filing Date

Tuesday, March 10, 2026

Filed 4 days after trade

HEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES

About Bausch & Lomb Corp

Company Overview

No company information available
View news mentioning BLCO

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4666452

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime